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Abstract 
Background:  To evaluate the role of low dose 
erythropoietin in the management of drug induced anemia 
and thus in adherence and continuation of antiviral 
treatment. 
Methods:  In this descriptive study 370 patients with 
chronic hepatitis C were included . All patients were given 
conventional Interferon Alpha-2b plus Ribavirin for 24 
weeks.  Haemoglobin estimation was done on day 0 and at 
2 weekly interval for first month and then monthly for 5 
months. Erythropoietin was given to patients with Hb 
level of 7 gm/dl and less. The study end points were to 
assess the Interferon maintenance and change in Hb.  
Results:  Out of the 370 patients treated with Interferon 
Alpha-2b plus Ribavirin, (n=31 patients) 8% were treated 
with erythropoietin. During erythropoietin treatment the 
Hb initial mean was 7 gm/dl and improvement of 2gm/dl 
or more than 2 gm/dl  was the end point. In 3 patients, Hb 
dropped further inspite of erythropoietin treatment, while 
in 26 patients, Hb improved with erythropoietin treatment. 
The optimal dose of Ribavirin was maintained in 29 
patients throughout the treatment. In 2 patients, Ribavirin 
dose was decreased due to anaemia not responding to 
erythropoietin. 
Conclusion: Even low doses of erythropoietin are 
effective in improving or maintaining haemoglobin levels 
in patients with treatment induced anaemia . Reduction of 
severity of treatment-induced anaemia with erythropoietin 
has been shown to encourage adherence and to enable 
patients to remain on higher doses of antiviral treatment. 
Key Words: HCV infection, Erythropoietin, Antiviral 
treatment (Interferon alpha 2-b plus Ribavirin).  
 
Introduction 
     Hepatitis C virus (HCV) infection is increasingly 
recognized as a major health care problem, and is 
found frequently in Pakistani settings.1  Standard 
treatment for chronic HCV involves an interferon-
based preparation and ribavirin for 24 to 48weeks.  
     The goal of therapy is to prevent complications and 
death from HCV infection. Several types of virological 
responses may occur, labeled according to their timing 
relative to treatment. The most important is the 
sustained virological response (SVR), defined as the 
absence of HCV RNA from serum by a sensitive PCR 
assay 24 weeks following discontinuation of therapy. 
An early virological response (EVR) is defined as a _2 
log reduction or complete absence of serum HCV RNA 
at week 12 of therapy compared with the baseline 
level. Failure to achieve an EVR is the most accurate 
predictor of not achieving an SVR. Undetectable virus 
at the end of either a 24-week or 48-week course of 
therapy is referred to as an end-of treatment response 
(ETR). An ETR does not accurately predict that an SVR 
will be achieved but is necessary for it to occur.2 
     Maximizing response rates to HCV therapy 
requires full treatment adherence to both Interferon 
and Ribavarin.3 Among the hematologic abnormalities 
associated with combination therapy, anemia is 
probably the most significant side effect.4 Significant 
anemia associated with ribavirin therapy can increase 
fatigue, has a demonstrable effect on quality of life, 
and is a frequent indication for dose reduction of 
ribavirin. A number of studies in patients undergoing 
therapy for hepatitis C have suggested that 
erythropoietin alfa can relieve many of the symptoms 
related to anemia.5 
 
Patients and Methods 
     This descriptive study was conducted from June 
2005 to December 2008 at the Department of General 
Medicine, Federal Government Polyclinic, Islamabad. 
A total of 370 patients, with chronic hepatitis C , were 
included in the study. Patients included in this study 
were of both genders found out to be HCV positive on 
Qualitative PCR, had no contraindication to give 
Interferon Alpha like Low Hb (<10mg/dl), 
pancytopenia, moderate or severe depression or 
decompensated liver disease, Patients who had fall of 
Hb level of <7 mg/dl after starting Interferon 
treatment, no contraindication to start Erythropoietin 
like uncontrolled high blood pressure, or 
hypersensitivity. Patients with others causes of 
anaemia and no regular follow up were excluded from 
this study group. All patients were given conventional 
Interferon Alpha-2b plus Ribavarin for 24 weeks with 
definitive indication of treatment and no 
contraindication to the antiviral treatment. 
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Haemoglobin(Hb)  levels were checked two weekly in 
all patients receiving antiviral treatment in first month 
of treatment and then once monthly thereafter. Cut off 
level of hemoglobin for the definition of anemia was 
set at the level of 12gm/dl, below which all patients 
would be considered anemic. The patients who were 
candidates to receive Epo had Hb level of 7gm/dl or 
belowThe adherence to antiviral treatment was 
monitored in patients who had severe anemia for 
which they received Erythropoietin. Erythropoietin 
was given to all patients with Hb level of 7 gm/ dl 
and below after ruling out other causes of anemia. A 
total dose of 4000 units subcutaneously three times 
per week was used. Pre treatment and post treatment 
HCV PCR were done to evaluate for   early 
virological response (EVR),  end of treatment 
response (ETR) and sustained viral response ( SVR).  
 
Results 
     Out of 370 patients, 188(51%) were males and 182 
(49%) were females.Anaemia was found in 267(72%). 
Out of 267 patients who had anemia, 165 (61.79%)  had 
Hb level between 10 – 11.9 gm/dl(Table 1). Out of 267 
patients 31 received erythropoietin .Out of these, 26 
had an improvement in haemoglobin levels (Table 
2).Twenty nine patients (99%) continued the treatment. 
Two patients who were admitted in the medical 
department for the treatment of anemia with Hb of 4 
gm/dl were excluded from study due to no regular 
follow up.EVR was achieved in 75% (p value .003) 
patients and ETR was achieved in 77% patients (p 
value 004). 69% patients achieved SVR (p value 007).  
 
Table 1: Haemoglobin levels in chronic  
hepatitis C patients 
Haemoglobin (g/dl) No(%) 
12-10 165 (61) 
<10-8 60 (22) 




     Treating Hepatitis C patients is still a challenge due 
to the high rate of adverse events. Among the adverse 
events of treatment, RBV induced haemolytic anaemia 
is of particular importance as it accounts for up to 36% 
of HCV treatment interruptions.6 Recombinant human 
erythropoietin (EPO), as adjuvant therapy during peg 
IFN and RBV therapy, is suggested in cases with 
treatment associated anaemia ad guidelines are 
suggested.  
 
Table 2: Chronic Hepatitis C and 
 Erythropoietin Therapy 
Characteristic  No  
Total patients 370 
Patients who developed anaemia 267 
Patients who received Erythropoietin 31 
Hb improvement by Erythropoietin  26 
No response to Erythropoietin 3 
Ribavirin dose maintained while on 
Erythropoietin 
29 
Riabavirin dose decreased while on 
Erythropoietin 
2 
Early virological response(EVR)* 75% 
End of Treatment Response**  77% 
Sustained Viral Response (SVR)*** 69* 
*EVR=Early Virological Response. It means HCV RNA cannot be 
detected in the blood at week 12 of treatment (complete EVR) or 
HCV RNA drops by more than 2 logs (100 times) from the baseline 
level by week 12 (partial EVR). Not reaching EVR predicts a low 
likelihood of achieving viral cure;**ETR=End of Treatment  
Response. It means HCV RNA is not detected in the blood at the end 
of treatment.***SVR=Sustained Viral Response. It means HCV RNA 
is not detected six months after treatment ends.  
     Recombinant EPO (erythropoietin alfa,) is a  
preparation of a physiological endogenous erythroid   
 growth factor, and most clinicians are familiar with its 
use in the treatment of anemia in chronic renal failure 
and end-stage renal disease.7-9 In terms of efficacy, 
under the ideal conditions of a clinical trial, it cannot 
be disputed that EPO improves hemoglobin levels in 
the setting of HCV treatment. Quality of life scores 
have also been reported to be better in those receiving 
EPO compared with those who did not.10,11 Studies 
revealed significant improvement in Hb levels in those 
who received EPO. Epoetin α in the treatment of HCV 
may not only increase but maintains hemoglobin 
levels in many patients without requiring RBV dose 
reduction or discontinuation. 11-15 
    In present study, a high incidence (72%) of patients 
had experienced anaemia out of which 11% had severe 
anaemia due to antiviral therapy but erythropoietin 
therapy for severe anaemia in these patients was 
significantly correlated with achieving ETR & SVR. 
Another aspect of the study which needs attention 
here is that we gave EPO to very selective patients 
(only 8%) who had Hb level below 7g/dl although 
according to other International studies available, 
patients received EPO on Hb level of 10g/dl and 
below instead of 7gm/dl and below as we chose. The 
reason for selecting such a low level of Hb for 
initiation of EPO is that being in a third world country 
with limited resources, we need to reserve EPO only 
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for severely anaemic patients keeping in view the high 
cost of EPO. In present study a dose of 4000 units 
thrice weekly was used. Treatment was discontinued 
in less 1% patients due to anaemia and statistically 
significant number of patients continued treatment 
even with Hb below 7gm/dl. The reason could be that 
our population either doesn’t develop constitutional 
symptoms or they have a good tolerance for this level 
of low Hb. Not only this but our patients also showed 
a good response to low doses of erythropoietin 
therapy as shown by percentage of people who 
achieved EVR, ETR and SVR. In our study, drop of Hb 
was from 12 gm/dl. So in this way, a drop of between 
3 and 5 gm/dl from the set standard of 12gm/dl, 
means Hb of below 9 and 7 gm/dl respectively as 
compared to drop of same ranges from 14-16gms/dl, 
which is between 11 -13gms/dl and below 9-11gms in 
the international study, which is a near normal Hb 
level for our population. 16   
     In present study the  dose of Ribavirin, in patients 
developing anemia is contrary to an assumption to 
reduce the dose.17  This could further increase the SVR 
rates in our study along with EPO use. Internationally 
recommended dose of erythropoietin is 40,000 Units 
subcutaneously once weekly.  We used small doses of 
erythropoietin that is 4000 Units subcutaneously 3 
times weekly, which is supported by a trial, in which a 
similar dose of erythropoietin was, used. 18 
 
Conclusion 
Even low doses of erythropoietin are effective in 
improving or maintiang the haemoglobin level in 




1. Umar M , Bushra H, Ahmad M. Hepatitis C in Pakistan: A 
review of available data. Hepatitis monthly. 
2010;10(3):205-14.  
2. Ghany MG, Strader DB, Thomas DL. Diagnosis, 
management, and treatment of hepatitis c:an update. AASLD 
practice guidelines. Hepatology. 2009;49(4):1335-73. 
3. Sherman M. Management of chronic hepatitis C: consensus 
guidelines. Can J Gastroenterol. 2007;21(c):25c-34c. 
4. Ong JP, Younossi ZM. Managing the hematologic side effects 
of antiviral therapy for chronic hepatitis C: anemia, 
neutropenia, and thrombocytopenia. Cleveland Clinic 
Journal of Medicine. 2004;71(3): 17-21. 
5. Itri lM. The use of epoetin alfa in chemotherapy patients: a 
consistent profile of efficacy and safety. Semin Oncol 
2002;29:81-87. 
6. Yoshida EM. Erythropoietin and hepatitis C therapy: Useful 
adjuvant therapy but remember to treat the patient and not 
just a number. Can J Gastroenterol, 2006; 20(8): 519–20. 
7. Sherman M, Cohen L, Cooper MA. Recommendations for the 
use of recombinant human erythropoietin in patients with 
hepatitis C virus being treated with ribavirin. Can J 
Gastroenterol. 2006;20:479–85. 
8. NKF-K/DOQI Clinical Practice Guidelines for Anemia of 
Chronic Kidney Disease: Update 2000. Am J Kidney Dis. 
2001;37(1 Suppl 1):182–238. 
9. Dieterich DT, Wasserman R, Brau N. Once-weekly epoetin 
alfa improves anemia and facilitates maintenance of 
ribavirin dosing in hepatitis C virus-infected patients 
receiving ribavirin plus interferon alfa. Am J Gastroenterol. 
2003;98:2491–99. 
10. Afdhal NH, Dieterich DT, Pockros PJ. Proactive Study Group 
Epoetin alfa maintains ribavirin dose in HCV-infected 
patients: A prospective double-blind, randomized controlled 
study. Gastroenterology. 2004;126:1302–11. 
11. Fung S, Kaita K, Wong F. Effect of erythropoietin-alpha on 
sustained virologic response in patients with chronic 
hepatitis C treated with pegylated interferon and ribavirin. 
Can J Gastroenterol. 2006;20:199. 
12. Talal AH, Weisz K, Hau T. A preliminary study of 
erythropoietin for anemia associated with ribavirin and 
interferon. Am JGastroenterol 2001;96:2802–04. 
13. Gergely AE, Lafarge P, Fouchard-Hubert I. Treatment of 
ribavirin/interferon-induced anemia with erythropoietin in 
patients with hepatitis C. Hepatology 2002;35:1281–82. 
14. Senkbeil LE, Moss JG, Gaglio P. Erythropoietin maintains 
ribavirin dose and sustained virologic response during HCV 
treatment . Hepatology 2003;38 ( 1):744- 48 
15. Younossi ZM, Ong JP, Collantes R. Darbepoetin alfa for 
ribavirin-induced anemia in patients with chronic hepatitis 
C treated with pegylated interferon and ribavirin . 
Gastroenterology 2004;126( 2):83-88  
16. Sulkowski MS, Wasserman R, Brooks L, Ball L. Changes in 
hemoglobin during interferon alpha-2b plus ribavirin 
combination therapy for chronic hepatitis C virus infection. 
J Viral Hepat  2004;11: 243–50. 
17. Soest HV, Renooij W, Van Erpecum KJ. Clinical and basal 
aspects of anemia during antiviral therapy for hepatitis C: 
Original Article. Annals of Hepatology 2009;8(4):316-24. 
18. Lebray P, Pichard A, Broissand C. Usefulness of 
erythropoietin and G-CSF during treatment for chronic 
hepatitis C with pegylated interferon. Hepatology 2002;36( 
4):1644- 49. 
 
